BTIG analyst Julian Harrison upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of ...

The mechanisms underlying skin renewal are still poorly understood. Interleukin-38 (IL-38), a protein involved in regulating inflammatory responses, could be a game changer. A team has observed it for ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Monday, November 18, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Thermo ...

The mechanisms underlying skin renewal are still poorly understood. Interleukin-38 (IL-38), a protein involved in regulating inflammatory responses, could be a game changer.

This compound comes in both form and gel form and garnered its first FDA approval in 2022. Zoryve is now approved to treat ...

CRANBURY, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MJH Life Sciences ®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic ...

The licensing deal with Biosion involves an experimental treatment for severe asthma and skin disorder known as atopic ...

Featured alongside Moore in the first phase of Moments of Clarity was Anna, a 12-year-old with atopic dermatitis (AD), the ...

against rheumatoid arthritis and atopic dermatitis. AbbVie’s immunology treatments generate approximately 50% of total revenue, oncology products contribute about 30%, neuroscience adds roughly 10%, ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...